The dilemma for patients with chronic hepatitis C: Treat now or warehouse?

Digestive and Liver Disease

Volumn 46, Issue 1, 2014, Pages 27-29

  Alberti, Alfredo ^a   Colombo, Massimo ^b   Craxì, Antonio ^c   Rizzetto, Mario ^d  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 450; BOCEPREVIR; LEDIPASVIR; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; SOFOSBUVIR; TELAPREVIR;

ANTIVIRAL THERAPY; DRUG EFFICACY; EDITORIAL; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RETREATMENT; STAGING;

ANTIVIRAL AGENTS; DRUG CARRIERS; DRUG DISCOVERY; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROLINE; PROTEASE INHIBITORS; RIBAVIRIN; TIME FACTORS; WATCHFUL WAITING;

EID: 84892164756     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2013.10.006     Document Type: Note

References (13)

1. Grassi E., Aghemo A. How to optimize HCV therapy in genotype 2 patients. Liver International 2013, 33:35-40.
2. Aghemo A., De Francesco R. New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Hepatology 2013, 58:428-438.
3. McGowan C.E., Monis A., Bacon B.R., et al. A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care. Hepatology 2013, 57:1325-1332.
4. Bini E.J., Brau N., Currie S., et al. Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. The American Journal of Gastroenterology 2005, 100:1772-1779.
5. Chou R., Hartung D., Rahman B., Wasson N., et al. Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review. Annals of Internal Medicine 2013, 158:114-123.
6. Coco B., Caraceni P., Aghemo A., et al. Triple therapy (Peg-interferon alpha+Ribavirin+first-generation protease inhibitor) for patients with HCV-genotype 1 chronic hepatitis: indications of the Italian Association for the Study of Liver Disease (AISF). Digestive and Liver Disease 2013.
7. Kittner J.M., Weiss N.M., Wiltink J., et al. Defer or treat? Reasons for treatment decisions in patients with chronic hepatitis C genotype 1 in the early era of directly acting antiviral agents. Digestive and Liver Disease 2013, 46:67-71.
8. Gilead reports interim data from phase 2 LONESTAR study. http://www.gilead.com/news/press-releases/2013/5/gilead-reports-interim-data-from-phase-2-lonestar-study%23sthash.uLTvDM4y.dpuf.
9. Lawitz E., Mangia A., Wyles D., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. The New England Journal of Medicine 2013, 368:1878-1887.
10. Jacobson I.M., Gordon S.C., Kowdley K.V., et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. The New England Journal of Medicine 2013, 368:1867-1877.
11. Kowdley K., Lawitz E., Poordad F., et al. Safety and efficacy of interferon-free regimens of ABT-450/r, ABT-267, ABT-333 +/- ribavirin in patients with chronic HCV GT1 infection: results from the aviator study. Journal of Hepatology 2013, 58:S2.
12. Zeuzem S., Soriano V., Asselah T., et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. The New England Journal of Medicine 2013, 369:630-639.
13. Aronsohn A., Jensen D. Distributive justice and the arrival of direct-acting antivirals: who should be first in line. Hepatology 2011, 53:1789-1791.